The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases
Advanced glycation end products (AGEs) are a class of compounds formed by nonenzymatic interactions between reducing sugars and proteins, lipids, or nucleic acids. AGEs can alter the protein structure and activate one of their receptors, specifically the receptor for advanced glycation end products...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/3/2894 |
| _version_ | 1797624219842904064 |
|---|---|
| author | Charlotte Delrue Reinhart Speeckaert Joris R. Delanghe Marijn M. Speeckaert |
| author_facet | Charlotte Delrue Reinhart Speeckaert Joris R. Delanghe Marijn M. Speeckaert |
| author_sort | Charlotte Delrue |
| collection | DOAJ |
| description | Advanced glycation end products (AGEs) are a class of compounds formed by nonenzymatic interactions between reducing sugars and proteins, lipids, or nucleic acids. AGEs can alter the protein structure and activate one of their receptors, specifically the receptor for advanced glycation end products (RAGE). These phenomena impair the functions of cells, extracellular matrix, and tissues. RAGE is expressed by a variety of cells and has been linked to chronic inflammatory autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome. The soluble (s)RAGE cleavage product is a positively charged 48-kDa cleavage product that retains the ligand binding site but loses the transmembrane and signaling domains. By acting as a decoy, this soluble receptor inhibits the pro-inflammatory processes mediated by RAGE and its ligands. In the present review, we will give an overview of the role of AGEs, sRAGE, and RAGE polymorphisms in several rheumatic diseases. AGE overproduction may play a role in the pathogenesis and is linked to accelerated atherosclerosis. Low serum sRAGE concentrations are linked to an increased cardiovascular risk profile and a poor prognosis. Some RAGE polymorphisms may be associated with increased disease susceptibility. Finally, sRAGE levels can be used to track disease progression. |
| first_indexed | 2024-03-11T09:39:51Z |
| format | Article |
| id | doaj.art-5f4b7e9ddc6e4ef3a7ec3d31ba707763 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T09:39:51Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-5f4b7e9ddc6e4ef3a7ec3d31ba7077632023-11-16T17:03:55ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-02-01243289410.3390/ijms24032894The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic DiseasesCharlotte Delrue0Reinhart Speeckaert1Joris R. Delanghe2Marijn M. Speeckaert3Department of Nephrology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Dermatology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Diagnostic Sciences, Ghent University, 9000 Ghent, BelgiumDepartment of Nephrology, Ghent University Hospital, 9000 Ghent, BelgiumAdvanced glycation end products (AGEs) are a class of compounds formed by nonenzymatic interactions between reducing sugars and proteins, lipids, or nucleic acids. AGEs can alter the protein structure and activate one of their receptors, specifically the receptor for advanced glycation end products (RAGE). These phenomena impair the functions of cells, extracellular matrix, and tissues. RAGE is expressed by a variety of cells and has been linked to chronic inflammatory autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren’s syndrome. The soluble (s)RAGE cleavage product is a positively charged 48-kDa cleavage product that retains the ligand binding site but loses the transmembrane and signaling domains. By acting as a decoy, this soluble receptor inhibits the pro-inflammatory processes mediated by RAGE and its ligands. In the present review, we will give an overview of the role of AGEs, sRAGE, and RAGE polymorphisms in several rheumatic diseases. AGE overproduction may play a role in the pathogenesis and is linked to accelerated atherosclerosis. Low serum sRAGE concentrations are linked to an increased cardiovascular risk profile and a poor prognosis. Some RAGE polymorphisms may be associated with increased disease susceptibility. Finally, sRAGE levels can be used to track disease progression.https://www.mdpi.com/1422-0067/24/3/2894autoimmune inflammatory joint diseasecardiovascular riskcarboxyethyllysinecarboxymethyllysinemethylglyoxalpentosidine |
| spellingShingle | Charlotte Delrue Reinhart Speeckaert Joris R. Delanghe Marijn M. Speeckaert The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases International Journal of Molecular Sciences autoimmune inflammatory joint disease cardiovascular risk carboxyethyllysine carboxymethyllysine methylglyoxal pentosidine |
| title | The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases |
| title_full | The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases |
| title_fullStr | The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases |
| title_full_unstemmed | The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases |
| title_short | The Potential Influence of Advanced Glycation End Products and (s)RAGE in Rheumatic Diseases |
| title_sort | potential influence of advanced glycation end products and s rage in rheumatic diseases |
| topic | autoimmune inflammatory joint disease cardiovascular risk carboxyethyllysine carboxymethyllysine methylglyoxal pentosidine |
| url | https://www.mdpi.com/1422-0067/24/3/2894 |
| work_keys_str_mv | AT charlottedelrue thepotentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases AT reinhartspeeckaert thepotentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases AT jorisrdelanghe thepotentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases AT marijnmspeeckaert thepotentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases AT charlottedelrue potentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases AT reinhartspeeckaert potentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases AT jorisrdelanghe potentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases AT marijnmspeeckaert potentialinfluenceofadvancedglycationendproductsandsrageinrheumaticdiseases |